OTC NSAIDs Need Additional Label Warnings – FDA Advisory Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
Labels for over-the-counter NSAIDS need additional information about potential risks, panel members in a joint meeting of FDA’s Arthritis and Drug Safety and Risk Management advisory committees say. Data do not show naproxen has a lower CV thrombotic event risk compared to other NSAIDs, they say.